C
Cheng Zheng
Researcher at Novartis
Publications - 6
Citations - 465
Cheng Zheng is an academic researcher from Novartis. The author has contributed to research in topics: Ceritinib & Anaplastic lymphoma kinase. The author has an hindex of 3, co-authored 4 publications receiving 360 citations.
Papers
More filters
Journal ArticleDOI
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw,Tae Min Kim,Lucio Crinò,Cesare Gridelli,Katsuyuki Kiura,Geoffrey Liu,Silvia Novello,Alessandra Bearz,Oliver Gautschi,Tony Mok,Makoto Nishio,Giorgio V. Scagliotti,David R. Spigel,S. Deudon,Cheng Zheng,Serafino Pantano,Patrick Urban,Cristian Massacesi,Kalyanee Viraswami-Appanna,Enriqueta Felip +19 more
TL;DR: Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy and was compared with single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.
Journal ArticleDOI
Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
G.V. Scagliotti,Tae Min Kim,L. Crinò,G. Liu,C. Gridelli,Silvia Novello,K. Kiura,Alessandra Bearz,Oliver Gautschi,Enriqueta Felip,Makoto Nishio,David R. Spigel,Tony Mok,Patrick Urban,S. Deudon,Cheng Zheng,Alice T. Shaw +16 more
Journal ArticleDOI
Two Phase III Studies Evaluating Ceritinib in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-rearranged (ALK + ) Non-Small Cell Lung Cancer (NSCLC): ASCEND-4 and ASCEND-5
Alice T. Shaw,Daniel Shao-Weng Tan,Lucio Crinò,Enriqueta Felip,Tony Mok,Makoto Nishio,Luis Paz-Ares,Giorgio V. Scagliotti,David R. Spigel,Juergen Wolf,Yi-Long Wu,Gilberto de Castro,Paramita Sen,Cheng Zheng,Andrew K. Joe,Jean-Charles Soria +15 more
TL;DR: Two phase III, prospective, multicenter, randomized open-label studies designed to compare the anti-tumor activity of ceritinib with that of chemotherapy in adult pts with ALK+ advanced NSCLC who are either chemotherapy- and CRZ-naive or who have received prior chemotherapy andCRZ (ASCEND-5; NCT01828112).
Journal ArticleDOI
444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK +) NSCLC previously treated with CT and crizotinib (CRZ)
Tony Mok,G.V. Scagliotti,Tae Min Kim,L. Crinò,G. Liu,C. Gridelli,Silvia Novello,K. Kiura,Alessandra Bearz,Oliver Gautschi,E. Felip,Makoto Nishio,David R. Spigel,Patrick Urban,S. Deudon,Cheng Zheng,Alice T. Shaw +16 more
Journal ArticleDOI
Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis – a population based analysis
Xinghui Li,Zhiqiang Chen,Yue Zhang,Long Zhang,Haiyan Niu,Cheng Zheng,Xiaoying Jing,Huidong Qiao,Guan-Hua Wang,Wenjun Yang +9 more
TL;DR: In this paper , the authors evaluated the effect of multimodal chemotherapy on the survival of gastric cancer patients with liver metastases (LMGC) and found that palliative chemotherapy was a significant independent prognostic factor in both the LM and non-LM groups.